{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:55:45Z","timestamp":1791078945266,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.jaad.2003.11.058","type":"journal-article","created":{"date-parts":[[2004,7,8]],"date-time":"2004-07-08T11:14:16Z","timestamp":1089285256000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Comparison of selective retinoic acid receptor\u2013 and retinoic X receptor\u2013mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma"],"prefix":"10.1016","volume":"51","author":[{"given":"Christiane","family":"Querfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Rademaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing B","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Posten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2003.11.058_BIB1","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas:a proposal from the cutaneous lymphoma study group of the European organization for research and treatment of cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2003.11.058_BIB2","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous T-cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.jaad.2003.11.058_BIB3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma:report of the international society for cutaneous lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0268-960X(03)00004-3","article-title":"Primary cutaneous lymphomas:a review with current treatment options","volume":"17","author":"Querfeld","year":"2003","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaad.2003.11.058_BIB5","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0968-0896(02)00083-4","article-title":"RAR-RXR selectivity and biological activity of new retinoic acid analogues with heterocyclic or polycyclic aromatic systems","volume":"10","author":"Ivanova","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jaad.2003.11.058_BIB6","first-page":"115","article-title":"The retinoid signaling pathway:molecular and genetic analysis","volume":"5","author":"Chambon","year":"1994","journal-title":"Semin Mol Biol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB7","first-page":"98","article-title":"Clinical applications of retinoids in cancer medicine","volume":"17","author":"Camacho","year":"2003","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.jaad.2003.11.058_BIB8","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199505253322103","article-title":"Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin","volume":"332","author":"Lotan","year":"1995","journal-title":"Engl J Med"},{"key":"10.1016\/j.jaad.2003.11.058_BIB9","first-page":"5479","article-title":"Modulation by retinoic acid (RA) of squamous cell differentiation, cellular RA-binding proteins, and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines","volume":"54","author":"Zou","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2003.11.058_BIB10","first-page":"106","article-title":"All-trans retinoic acid in hematological malignancies, an update","volume":"82","author":"Sacchi","year":"1997","journal-title":"Haematologica"},{"key":"10.1016\/j.jaad.2003.11.058_BIB11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1200\/JCO.1994.12.6.1185","article-title":"Use of retinoic acids in the treatment of peripheral T-cell lymphoma:a pilot study","volume":"12","author":"Cheng","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB12","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/1097-0142(19910515)67:10<2490::AID-CNCR2820671017>3.0.CO;2-Q","article-title":"13-cis retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma","volume":"67","author":"Chow","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2003.11.058_BIB13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archderm.1987.01660260071016","article-title":"Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)","volume":"123","author":"Kessler","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2340\/0001555567232236","article-title":"Oral retinoids in mycosis fungoides and S\u00e9zary syndrome: a comparison of isotretinoin and etretinate; a study from the Scandinavian mycosis fungoides group","volume":"67","author":"Molin","year":"1987","journal-title":"Acta Derm Venerol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB15","series-title":"Retinoids: new trends in research and therapy","first-page":"34441","article-title":"13-cis-retinoic acid in mycosis fungoides","author":"Molin","year":"1985"},{"key":"10.1016\/j.jaad.2003.11.058_BIB16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2133.1983.tb03991.x","article-title":"Treatment of cutaneous lymphoma with etretinate","volume":"1099","author":"Claudy","year":"1983","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(83)92136-0","article-title":"Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid","volume":"1","author":"Kessler","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.11.058_BIB18","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","article-title":"Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF02505252","article-title":"Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA","volume":"288","author":"Rajan","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2003.11.058_BIB20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000204582","article-title":"Roferon-A in combination with Tigason in cutaneous T-cell lymphomas","volume":"89","author":"Dr\u00e9no","year":"1993","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB21","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0190-9622(92)70142-3","article-title":"Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome)","volume":"26","author":"Jones","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2133.1991.tb14772.x","article-title":"The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-\u03b12a and etretinate","volume":"125","author":"Dreno","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","article-title":"Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids","volume":"24","author":"Knobler","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB24","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon \u03b1-2a plus acitretin versus interferon \u03b1-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2003.11.058_BIB25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/1024533031000090801","article-title":"Acute promyelocytic leukemia: a case-based review","volume":"8","author":"Gupta","year":"2003","journal-title":"Hematology"},{"key":"10.1016\/j.jaad.2003.11.058_BIB26","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1097\/00002030-199816000-00012","article-title":"Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial; Kaposi's sarcoma ANRS study group (agence nationale de recherches sur le SIDA)","volume":"12","author":"Saiag","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2003.11.058_BIB27","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0301-472X(00)00546-4","article-title":"Retinoic acid-induced apoptoctic pathway in T-cell lymphoma: identification of four groups of genes with differential biological functions","volume":"28","author":"Wang","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/107999099314117","article-title":"Retinoids synergize with interleukin-2 to augment IFN-\u03b3 and interleukin-12 production by human peripheral blood mononuclear cells","volume":"19","author":"Fox","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jaad.2003.11.058_BIB29","first-page":"97a","article-title":"Phase II trial of all-trans retinoic acid in the treatment of relapsed\/refractory mycosis fungoides\/S\u00e9zary syndrome: proceedings of the American society of hematology","volume":"94","author":"Siegel","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2003.11.058_BIB30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2174\/1381612003400146","article-title":"Recent developments in receptor-selective retinoids","volume":"6","author":"Nagpal","year":"2000","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jaad.2003.11.058_BIB31","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/106002800103500903","article-title":"Oral bexarotene in the treatment of cutaneous T-cell lymphoma","volume":"35","author":"Wong","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2003.11.058_BIB32","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2003.11.058_BIB33","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB34","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T\u2013cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB36","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1210\/endo.143.8.8930","article-title":"Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat","volume":"14388","author":"Liu","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.jaad.2003.11.058_BIB37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/CDLI.6.1.79-84.1999","article-title":"Dysregulated synthesis of intracellular type 1 and 2 cytokines by T-cells of patients with cutaneous T-cell lymphoma","volume":"6","author":"Lee","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB38","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood.V87.2.725.bloodjournal872725","article-title":"Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein","volume":"87","author":"Kizaki","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2003.11.058_BIB39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/10428199709039029","article-title":"Retinoid resistance in leukemic cells","volume":"25","author":"Kizaki","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2003.11.058_BIB40","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood.V82.7.2175.2175","article-title":"Resistance to all-trans-retinoic acid (ATRA) therapy in relapsing acute promyeolocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells","volume":"82","author":"Delva","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2003.11.058_BIB41","first-page":"234","article-title":"Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P 450","volume":"26","author":"Howell","year":"1998","journal-title":"Drug Metab Disp"},{"key":"10.1016\/j.jaad.2003.11.058_BIB42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1997.15.2.790","article-title":"Initial clinical trial of a selective retinoid X receptor ligand, LGD 1069","volume":"15","author":"Miller","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2003.11.058_BIB43","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2002-01-0300","article-title":"Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox","volume":"100","author":"Gorgun","year":"2002","journal-title":"Blood"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203045389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203045389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:34:36Z","timestamp":1759268076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962203045389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0190962203045389"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2003.11.058","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of selective retinoic acid receptor\u2013 and retinoic X receptor\u2013mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2003.11.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}